Sudeep Pharma
Sudeep Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sudeep Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Sudeep Pharma Ltd trades at a P/E of 54.90×.
Valuation
Profitability
Growth
Financial Health
Sudeep Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Sudeep Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Sudeep Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹8,482.44 Cr and reported EPS of ₹14.30.
| Period | 2026 |
|---|---|
| Revenue from Operations | 642 |
| Other Income | 29 |
| Total Income | 671 |
| Cost of Goods Sold (COGS) | 227 |
| Gross Profit | 415 |
| +Operating Expenses | 193 |
| EBITDA | 222 |
| +Non-Operating Expenses | 22 |
| Profit Before Tax (PBT) | 228 |
| +Tax Expense | 54 |
| Profit After Tax (PAT) | 174 |
| Earnings Per Share (EPS) | 15.31 |
| Diluted Shares Outstanding (Nos.) | 11 |
| +Additional Disclosures | 670 |
| Material Cost % | 42 |
| Employee Cost % | 8 |
| Other Cost % | 22 |
| OPM % | 35 |
| Tax % | 24 |
| Gross Margin % | 0.00 |
| EBITDA Margin % | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Additional Fields | 207 |
Sudeep Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Sudeep Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sudeep Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Sudeep Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Sudeep Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
What you're getting.
No strengths or opportunities on record.
What can break it.
No weaknesses or threats on record.
What would change my mind.
Trim if P/E re-rates above 71. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 28%. The operating engine is no longer compounding capital efficiently.
Sudeep Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sudeep Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Sudeep Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sudeep Pharma Ltd — derived from the live tape, not yesterday's close.
Sudeep Pharma Ltd last traded at ₹749.5 with an intraday range of ₹737.35–₹764.45 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹749.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 817.72 | +68.22 | +9.10% |
| R3 | 790.62 | +41.12 | +5.49% |
| R2 | 777.53 | +28.03 | +3.74% |
| R1 | 763.52 | +14.02 | +1.87% |
| PIVOT | 750.43 | 0.93 | 0.12% |
| CURRENT | 749.50 | — | — |
| S1 | 682.22 | -67.28 | -8.98% |
| S2 | 709.32 | -40.18 | -5.36% |
| S3 | 723.33 | -26.17 | -3.49% |
| S4 | 736.42 | -13.08 | -1.75% |
SUDEEPPHRM is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 737.35 ~ 746.6
Trading Above opening range, showing Bullishness
Sudeep Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sudeep Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sudeep Pharma Ltd stood at 59.9% of traded volume, against a 20-day average of 50.7%.
Sudeep Pharma announcements: results, concalls, ratings, M&A.
Filings Sudeep Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sudeep Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 35 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Sudeep Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Dividend
Sudeep Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 21, 2026, recommended Final Dividend of Rs. 1.50…
Outcome of Board Meeting
Sudeep Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 21, 2026.
Investor decks & rating reports.
Sudeep Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sudeep Pharma has declared, sequenced by announce and record date.
Sudeep Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sudeep Pharma Ltd: business, sector, key facts.
What Sudeep Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sudeep Pharma Ltd is a listed Indian equity, listed as NSE: SUDEEPPHRM, BSE: 544619.
Sudeep Pharma Ltd
Questions investors ask about Sudeep Pharma Ltd (SUDEEPPHRM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sudeep Pharma Ltd (SUDEEPPHRM)?
The current share price of Sudeep Pharma Ltd (SUDEEPPHRM) is ₹749.5. Today, the stock has gained by ₹19.70 (2.70%), trading in a range of ₹737.35 to ₹764.45. The stock opened at ₹746.6 with a trading volume of 2,94,718 shares.
02Is Sudeep Pharma Ltd stock a good investment for long-term?
Sudeep Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹8,482.44 crores, P/E ratio of 54.90, ROE of 32.80%, and ROCE of 35.60%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sudeep Pharma Ltd stock?
The 52-week high price of Sudeep Pharma Ltd (SUDEEPPHRM) is ₹0, while the 52-week low is ₹0. Currently trading at ₹749.5, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sudeep Pharma Ltd stock at the current price?
Whether to buy Sudeep Pharma Ltd stock at ₹749.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 54.90 and P/B ratio of 0.00. Today's performance shows a gain of 2.70%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sudeep Pharma Ltd and when is the next dividend?
Sudeep Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹749.5, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sudeep Pharma Ltd?
Sudeep Pharma Ltd's key financial metrics include: P/E Ratio: 54.90, P/B Ratio: 0.00, ROE: 32.80%, ROCE: 35.60%, Dividend Yield: 0.00%, EPS: ₹14.30, Book Value: ₹0, and Debt-to-Equity: 0.28. The company's market cap stands at ₹8,482.44 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sudeep Pharma Ltd stock performing today in the market?
Sudeep Pharma Ltd stock opened at ₹746.6 and is currently trading at ₹749.5, showing a gain of ₹19.70 (2.70%). The intraday high is ₹764.45 and low is ₹737.35. The trading volume stands at 2,94,718 shares, indicating moderate market participation today.
08What is the P/E ratio of Sudeep Pharma Ltd and what does it indicate?
Sudeep Pharma Ltd has a Price-to-Earnings (P/E) ratio of 54.90, which means investors are willing to pay ₹54.90 for every ₹1 of earnings. With an EPS of ₹14.30, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sudeep Pharma Ltd (SUDEEPPHRM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy